<status value="draft"/><publisher value="HL7 International / Clinical Decision Support"/><contact><telecom><system value="url"/><value value="http://www.hl7.org/Special/committees/dss"/></telecom></contact><relatesTo><type><coding><system value="http://terminology.hl7.org/CodeSystem/artifact-relationship-type"/><code value="cites"/><display value="Cites"/></coding></type><targetMarkdown value="Figure 2 Lees 2016 Citation: Lees KR, Emberson J, Blackwell L, Bluhmki E, Davis SM, Donnan GA, et al; Stroke Thrombolysis Trialists’ Collaborators Group. Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials. Stroke. 2016;47:2373-2379. PMID 27507856 URL: https://doi.org/10.1161/STROKEAHA.116.013644"/></relatesTo><description value="mRS 0-2 at 90 days Odds Ratio 1.2 for Alteplase vs. No Alteplase in patients with acute ischemic stroke 3-4.5 hours prior"/><variableDefinition><variableRole value="population"/><observed><reference value="EvidenceVariable/Stroke-Thrombolysis-Trialists-2014-2016-IPD-MA-Cohort"/><type value="EvidenceVariable"/><display value="Stroke Thrombolysis Trialists’ 2014-2016 IPD-MA Cohort"/></observed><intended><reference value="Group/AcuteIschemicStroke3-4halfHours"/><type value="Group"/><display value="stroke at 3-4.5 hours"/></intended><directnessMatch><coding><system value="http://terminology.hl7.org/CodeSystem/directness"/><code value="moderate"/><display value="Moderate quality match between observed and intended variable"/></coding></directnessMatch></variableDefinition><variableDefinition><variableRole value="outcome"/><observed><reference value="EvidenceVariable/example-mRS0-2-at-90days"/><type value="EvidenceVariable"/><display value="mRS 0-2 at 90 days"/></observed><intended><reference value="EvidenceVariable/example-alive-independent-90day"/><type value="EvidenceVariable"/><display value="Alive and not functionally dependent at 90 days"/></intended></variableDefinition><variableDefinition><variableRole value="exposure"/><comparatorCategory value="No Alteplase"/><observed><reference value="EvidenceVariable/example-group-assignment-alteplase-for-stroke-vs-no-alteplase"/><type value="EvidenceVariable"/><display value="Group Assignment: Alteplase for Stroke vs No Alteplase"/></observed></variableDefinition><synthesisType><coding><system value="http://terminology.hl7.org/CodeSystem/synthesis-type"/><code value="IPD-MA"/><display value="individual patient data meta-analysis"/></coding></synthesisType><studyDesign><coding><system value="https://fevir.net/sevco"/><code value="SEVCO:01003"/><display value="randomized assignment"/></coding></studyDesign><statistic><statisticType><coding><system value="https://fevir.net/sevco"/><code value="STATO:0000182"/><display value="odds ratio"/></coding></statisticType><quantity><value value="1.2"/></quantity><sampleSize><numberOfStudies value="9"/></sampleSize><attributeEstimate><description value="95% CI 1.06 to 1.3"/><type><coding><system value="http://terminology.hl7.org/CodeSystem/attribute-estimate-type"/><code value="C53324"/><display value="Confidence interval"/></coding></type><level value="0.95"/><range><low><value value="1.06"/></low><high><value value="1.3"/></high></range></attributeEstimate></statistic><certainty><description value="Very low certainty due to risk of bias, inconsistency, imprecision, and indirectness"/><type><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-type"/><code value="Overall"/><display value="Overall certainty"/></coding></type><rating><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-rating"/><code value="very-low"/><display value="Very low quality"/></coding></rating><subcomponent><type><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-type"/><code value="PublicationBias"/><display value="Publication bias"/></coding></type><rating><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-rating"/><code value="no-concern"/><display value="no serious concern"/></coding></rating></subcomponent><subcomponent><note><text value="IST-3 had inconsistent results and contributed large proportion of data"/></note><type><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-type"/><code value="Inconsistency"/><display value="Inconsistency"/></coding></type><rating><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-rating"/><code value="serious-concern"/><display value="serious concern"/></coding></rating></subcomponent><subcomponent><note><text value="results derived from figure with limited data reported to support the specific effect estimate; derived odds ratio in figure does not match results from rates of mRS 0-2 reported in Supplementary Figure 3b"/></note><type><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-type"/><code value="Imprecision"/><display value="Imprecision"/></coding></type><rating><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-rating"/><code value="serious-concern"/><display value="serious concern"/></coding></rating></subcomponent><subcomponent><note><text value="resuts derived for 3 - 4.5 hours assume data from 0 - 6 hours is informative"/></note><type><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-type"/><code value="Indirectness"/><display value="Indirectness"/></coding></type><rating><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-rating"/><code value="serious-concern"/><display value="serious concern"/></coding></rating></subcomponent><subcomponent><note><text value="results largely influenced by IST-3 trial which was unblinded and ECASS III which had baseline imbalances"/></note><type><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-type"/><code value="RiskOfBias"/><display value="Risk of bias"/></coding></type><rating><coding><system value="http://terminology.hl7.org/CodeSystem/certainty-rating"/><code value="serious-concern"/><display value="serious concern"/></coding></rating></subcomponent></certainty></Evidence>

"Effect of Alteplase vs No alteplase on mRS 0-2 at 90 days in Stroke 3-4.5 hours prior" is a comparative effect estimate.